Clinical Trial: A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06981091) titled 'A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis' on May 12.

Brief Summary: The purpose of this study is to find out if XH-S004 can reduce pulmanary exacerbation over a 24-week treatment duration in participants with non-cystic fibrosis bronchiectasis.

Study Start Date: May 16

Study Type: INTERVENTIONAL

Condition: Non-Cystic Fibrosis Bronchiectasis

Intervention: OTHER: XH-S004 20 mg

Administered once per day for 24 weeks.

OTHER: XH-S004 40 mg

Administered once per day for...